RT Journal Article SR Electronic T1 The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines JF Gut JO Gut FD BMJ Publishing Group Ltd and British Society of Gastroenterology SP 1920 OP 1941 DO 10.1136/gutjnl-2018-316818 VO 67 IS 11 A1 Benjamin H Mullish A1 Mohammed Nabil Quraishi A1 Jonathan P Segal A1 Victoria L McCune A1 Melissa Baxter A1 Gemma L Marsden A1 David J Moore A1 Alaric Colville A1 Neeraj Bhala A1 Tariq H Iqbal A1 Christopher Settle A1 Graziella Kontkowski A1 Ailsa L Hart A1 Peter M Hawkey A1 Simon D Goldenberg A1 Horace R T Williams YR 2018 UL http://gut.bmj.com/content/67/11/1920.abstract AB Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.